The only Massachusetts biotech that's dared brave the public markets this year has grown significantly since its IPO.

After years of careful discipline during a tough economic period, Sionna Therapeutics Inc. is starting to flex its growth as the company heads toward some big clinical milestones with its treatments for cystic fibrosis.

Stream NBC10 Boston news for free, 24/7, wherever you are. WATCH HERE

More on this story from Boston Business Journal

See Full Page